Quince Therapeutics (QNCX) News Today $0.79 +0.01 (+1.29%) (As of 07/26/2024 ET) Add Compare Share Share HeadlinesStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 November 2021 October 2021 September 2021 August 2021 Time Period July 26 at 2:57 AM | americanbankingnews.comQuince Therapeutics (NASDAQ:QNCX) Stock Price Up 2.6%June 25, 2024 | businesswire.comQuince Therapeutics Announces First Patient Dosed in Phase 3 Clinical Trial of EryDex for the Treatment of Ataxia-TelangiectasiaJune 3, 2024 | businesswire.comQuince Therapeutics Receives U.S. FDA Fast Track Designation for EryDex SystemMay 13, 2024 | investorplace.comQNCX Stock Earnings: Quince Therapeutics Reported Results for Q1 2024May 13, 2024 | businesswire.comQuince Therapeutics Provides Business Update and Reports First Quarter 2024 Financial ResultsMay 6, 2024 | businesswire.comQuince Therapeutics to Present at The Citizens JMP Life Sciences ConferenceApril 25, 2024 | finance.yahoo.comQuince Therapeutics, Inc. (QNCX)April 2, 2024 | investorplace.comQNCX Stock Earnings: Quince Therapeutics Reported Results for Q4 2023April 1, 2024 | finance.yahoo.comQuince Therapeutics Provides Business Update and Reports Fourth Quarter and Fiscal 2023 Financial ResultsFebruary 22, 2024 | finance.yahoo.comQuince Therapeutics Launches Scientific Advisory BoardFebruary 22, 2024 | businesswire.comQuince Therapeutics Launches Scientific Advisory BoardFebruary 15, 2024 | finance.yahoo.comQuince Therapeutics Appoints Former Reata Pharmaceuticals Chief R&D Officer Dr. Rajiv Patni to its Board of DirectorsFebruary 15, 2024 | marketbeat.comQuince Therapeutics, Inc. (NASDAQ:QNCX) Sees Significant Drop in Short InterestQuince Therapeutics, Inc. (NASDAQ:QNCX - Get Free Report) was the target of a significant decrease in short interest in the month of January. As of January 31st, there was short interest totalling 1,900,000 shares, a decrease of 7.3% from the January 15th total of 2,050,000 shares. Currently, 6.0% of the company's shares are sold short. Based on an average trading volume of 91,100 shares, the days-to-cover ratio is presently 20.9 days.February 15, 2024 | businesswire.comQuince Therapeutics Appoints Former Reata Pharmaceuticals Chief R&D Officer Dr. Rajiv Patni to its Board of DirectorsFebruary 14, 2024 | marketbeat.comQuince Therapeutics (NASDAQ:QNCX) Stock Price Down 8.5%Quince Therapeutics (NASDAQ:QNCX) Stock Price Down 8.5%January 4, 2024 | finance.yahoo.comQuince Therapeutics to Participate at Investor Events in January 2024November 11, 2023 | morningstar.comQuince Therapeutics Inc QNCXOctober 27, 2023 | benzinga.comChief Business Officer and COO at Quince Therapeutics Acquires Company Stock Options Worth 75,000 SharesOctober 25, 2023 | benzinga.comQuince Therapeutics Chief Scientific Officer Awarded $291K Worth of Stock OptionsOctober 23, 2023 | finance.yahoo.comQuince Therapeutics Completes Acquisition of EryDel S.p.A.September 28, 2023 | msn.comFDA lifts partial clinical hold on EryDel lead product EryDexSeptember 28, 2023 | finance.yahoo.comU.S. FDA Partial Clinical Hold Lifted on IND for EryDel’s Lead Phase 3 Asset EryDex for the Treatment of Ataxia-TelangiectasiaSeptember 7, 2023 | benzinga.comQuince Therapeutics President Awarded $692K Worth of Stock OptionsSeptember 6, 2023 | bizjournals.comDaily Digest: Currys aim to raise $50M for Oakland schools; Sotheby's opens new officeSeptember 6, 2023 | finance.yahoo.comQuince Therapeutics Appoints Dr. Charles S. Ryan as PresidentAugust 18, 2023 | benzinga.com325K Reasons To Be Bullish On Quince Therapeutics StockAugust 14, 2023 | benzinga.comQuince Therapeutics And 2 Other Stocks Under $3 Insiders Are BuyingAugust 11, 2023 | finance.yahoo.comQuince Therapeutics to Present at Sidoti Virtual Investor Conference on August 17, 2023July 26, 2023 | finanznachrichten.deQUINCE THERAPEUTICS INCJuly 24, 2023 | benzinga.comWhat's Going On With Quince Therapeutics Stock TodayJuly 24, 2023 | finance.yahoo.comQuince Therapeutics to Acquire EryDel SpA and its Phase 3 Asset Targeting Ataxia-Telangiectasia with No Currently Approved Treatments and Estimated $1+ Billion Peak Sales OpportunityJuly 13, 2023 | msn.comEcho Lake bumps up bid to buy Quince Therapeutics to $1.80July 13, 2023 | seekingalpha.comEcho Lake bumps up bid to buy Quince Therapeutics to $1.80/shareJuly 13, 2023 | finance.yahoo.comEcho Lake Capital Increase Offer to Acquire Quince Therapeutics, Inc.June 6, 2023 | finanznachrichten.deEcho Lake Capital: Echo Lake Criticizes Quince Therapeutics Board for Enriching Themselves While Destroying Significant Shareholder ValueJune 6, 2023 | finance.yahoo.comEcho Lake Criticizes Quince Therapeutics Board for Enriching Themselves While Destroying Significant Shareholder ValueApril 11, 2023 | finance.yahoo.comQuince Therapeutics Board of Directors Unanimously Rejects Unsolicited Proposal from Echo Lake CapitalApril 6, 2023 | seekingalpha.comQuince Therapeutics: A Company Without A Suitable PlanApril 6, 2023 | bizjournals.comCash-rich life sciences companies are targets. Activist investors are taking aim.April 6, 2023 | finance.yahoo.comQuince Therapeutics Engages MTS Health Partners as Independent Financial AdvisorApril 5, 2023 | seekingalpha.comQuince Therapeutics adopts poison pill amid unsolicited takeover offerApril 5, 2023 | finance.yahoo.comQuince Therapeutics Adopts Limited Duration Stockholders Rights PlanMarch 22, 2023 | businesswire.comQuince Therapeutics Confirms Receipt of Unsolicited Acquisition Offer from Echo Lake CapitalMarch 21, 2023 | benzinga.comQuince Therapeutics shares are trading higher after Echo Lake Capital offered to acquire the company for $1.60 per share in cash.March 21, 2023 | msn.comQuince stock surges ~50% on acquisition offer from Echo Lake CapitalMarch 21, 2023 | finance.yahoo.comEcho Lake Capital Offers to Acquire Quince Therapeutics, Inc.January 30, 2023 | msn.comQuince expects ~$11M annual capital and operating expenditures in 2023January 30, 2023 | finance.yahoo.comQuince Therapeutics Provides Pipeline Update and Business Outlook for 2023January 27, 2023 | bizjournals.comCasey Lynch and her Cortexyme team regroup at Lighthouse for another shot at Alzheimer'sJanuary 27, 2023 | investorplace.comWhy Is Quince Therapeutics (NASDAQ:QNCX) Stock Up 53% Today? Get Quince Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for QNCX and its competitors with MarketBeat's FREE daily newsletter. Email Address Nvidia insiders dumping shares (Ad)All the signs show the AI market is about to reverse. And unless you know what’s really going on in this sector, you could be wiped out. Inside this new expose, you'll discover exactly how the AI crisis will unfold... how you can prepare for it before it's too late... and how you can potentially profit from it, too. Click here to read the new expose, The Big AI Die-Up while you still can. To see Porter Stansberry's new AI prediction go here now. QNCX Media Mentions By Week QNCX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. QNCX News Sentiment▼1.890.62▲Average Medical News Sentiment QNCX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. QNCX Articles This Week▼20▲QNCX Articles Average Week Get Quince Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for QNCX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Verastem News Vistagen Therapeutics News Vaxart News Athira Pharma News X4 Pharmaceuticals News Opthea News Tevogen Bio News Cellectis News Cardiff Oncology News Omega Therapeutics News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:QNCX) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Quince Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Quince Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free QNCX Stock Alerts